Share

|

|

|

Baricitinib disappoints in SLE-BRAVE trials

Baricitinib has achieved largely negative results in the SLE-BRAVE trials, published in The Lancet.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

Reflux symptoms predict interstitial lung disease progression in SSc

Post-hoc analysis of a randomised trial shows that the severity of reflux symptoms in patients with systemic sclerosis predicts radiographic progression of interstitial lung disease.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

Research identifies sex differences in SSc-ILD outcomes

Men with systemic sclerosis-associated interstitial lung disease may have a more severe disease course than women, whereas women with the condition could be more likely to experience certain adverse events when treated with immunosuppressive therapy, suggest findings from two studies.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

Study identifies sex differences in RA remission rates

Men with rheumatoid arthritis initiating treatment with biologic or targeted synthetic DMARDs may be more likely to achieve remission than women, suggests research reported at The Lancet Summit: Sex and gender in rheumatology.